^
    Evidence Level:
    Sensitive: C3 – Early Trials

    [PD-L1 expression-Non Small Cell Lung Cancer-pembrolizumab]

    Source:
    ASCO 2022
    Test:

    nCounter® PanCancer IO 360™ Panel

    Title:
    PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 < 50%: A multiomics approach.
    Published date:
    05/26/2022
    Excerpt:
    Median follow up and PFS were 26.4 and 2.9 months, respectively….To the best of our knowledge, this is the first prospective trial in NSCLC with PD-L1 < 50% performed with a multiomic approach able to identify immune cell subsets and expression levels of genes associated to PFS under first line treatment with pembrolizumab.
    DOI:
    10.1200/JCO.2022.40.16_suppl.9051
    Trial ID:
    PEOPLE